{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-187012","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.950143+00:00","generated_at":"2026-05-15T03:05:15.133139+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track","bullets":["Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.","Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.","DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.","DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.","David Shapiro, M.D., appointed to board of directors in March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-187012","json":"https://secwatch.observer/filing/0001193125-26-187012.json","markdown":"https://secwatch.observer/filing/0001193125-26-187012.md","text":"https://secwatch.observer/filing/0001193125-26-187012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:05:15.133139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37168189c14500d81bcc42c7bc265d31bd2519e0","claim":"Design Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income Net loss was $17.6 million for the quarter ended March 31, 2026..","evidence_excerpt":"Net loss was $17.6 million for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"Net loss was $17.6 million for the quarter ended March 31, 2026."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}